Related Experiment Video
Updated: May 9, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Canine cytochrome P-450 pharmacogenetics.
1Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA 99164, USA. Michael.Court@vetmed.wsu.edu
Summary
Genetic variations in cytochrome P-450 (CYP) enzymes significantly impact drug metabolism in dogs, leading to varied responses and potential adverse drug reactions. Understanding these canine CYP polymorphisms is crucial for effective veterinary drug therapy.
Area of Science:
- Pharmacogenomics
- Veterinary Pharmacology
- Drug Metabolism
Background:
- Cytochrome P-450 (CYP) enzymes are critical for drug elimination in mammals.
- Interindividual variability in CYP activity, due to induction, inhibition, and genetic polymorphism, affects drug efficacy and safety.
- Significant species-specific differences in CYP expression and substrate specificity exist between humans and dogs.
Purpose of the Study:
- To review existing literature on genetic polymorphisms in canine CYP enzymes.
- To assess the impact of these polymorphisms on CYP-dependent drug metabolism in dogs.
- To compare human and dog CYP differences in the context of genetic variations.
Main Methods:
- Literature review of published data on canine CYP genetic polymorphisms.
- Analysis of studies investigating CYP enzyme activity and substrate specificity in dogs.
- Comparative analysis of human and canine CYP genetic data.
Main Results:
- Genetic polymorphisms are present in various canine CYP enzymes.
- These polymorphisms contribute to significant interindividual variability in drug metabolism in dogs.
- Known human-dog CYP differences are further complicated by canine-specific genetic variations.
Conclusions:
- Canine CYP genetic polymorphisms play a substantial role in drug metabolism variability.
- Understanding these polymorphisms is essential for predicting drug response and minimizing adverse events in veterinary medicine.
- Further research is needed to fully elucidate the clinical implications of canine CYP pharmacogenomics.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...